News
CADL
4.800
-3.03%
-0.150
Weekly Report: what happened at CADL last week (0330-0403)?
Weekly Report · 4d ago
Candel Therapeutics grants 70,000 inducement stock options to five new employees
Reuters · 04/02 20:08
CANDEL THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/02 20:05
Weekly Report: what happened at CADL last week (0323-0327)?
Weekly Report · 03/30 09:41
Weekly Report: what happened at CADL last week (0316-0320)?
Weekly Report · 03/23 09:39
Candel Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 03/18 15:13
Candel Therapeutics Price Target Raised to $26.00/Share From $22.00 by Citigroup
Dow Jones · 03/18 15:13
Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26
Benzinga · 03/18 15:03
Candel Therapeutics price target raised to $26 from $22 at Citi
TipRanks · 03/18 10:22
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
Reuters · 03/18 07:36
Candel gains on additional mid-stage trial data for lead asset
Seeking Alpha · 03/17 18:01
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
TipRanks · 03/17 15:25
Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline
Reuters · 03/17 12:26
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
TipRanks · 03/17 12:22
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Non-Small Cell Lung Cancer Treatment
Benzinga · 03/17 12:12
CANDEL THERAPEUTICS INC: PHASE 3 PIVOTAL STUDY PLANNED FOR INITIATION IN Q2 2026
Reuters · 03/17 12:12
Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial
Reuters · 03/17 12:06
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Barchart · 03/17 07:05
Weekly Report: what happened at CADL last week (0309-0313)?
Weekly Report · 03/16 09:39
Candel Therapeutics Price Target Cut to $22.00/Share From $24.00 by Citigroup
Dow Jones · 03/13 20:18
More
Webull provides a variety of real-time CADL stock news. You can receive the latest news about Candel Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.